NCT03794492View on ClinicalTrials.gov

Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome

PHASE4CompletedINTERVENTIONAL
Enrollment

169

Participants

Timeline

Start Date

March 31, 2018

Primary Completion Date

July 22, 2022

Study Completion Date

April 27, 2023

Conditions
Kidney Transplant
Interventions
DRUG

Mycophenolate mofetil 500mg Tab. or 250mg Cap.

\- Orally, up to 1g BID(total 2g daily)

DRUG

Tacrolimus

\- Orally, check the blood ceocentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3-8ng/ml

DRUG

Methylprednisolone/prednisolone

\- Methyprednisolone 500mg / Prednisolone 5mg

DRUG

Basiliximab

\- IV, 20mg(before Kidney transplat) / 20mg(Day 4 of kidney transplant)

Trial Locations (1)

Unknown

Ajou University Hospital, Suwan

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY